» Articles » PMID: 28993766

Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis

Overview
Journal Front Immunol
Date 2017 Oct 11
PMID 28993766
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Induced costimulatory ligand (ICOSL) plays an important role in the activation of T cells through its interaction with the inducible costimulator, ICOS. Suppression of full T cell activation can be achieved by blocking this interaction and has been shown to be an effective means of ameliorating disease in models of autoimmunity and inflammation. In this study, we demonstrated the ability of a novel class of anti-ICOSL antigen-binding single domains derived from sharks (VNARs) to effectively reduce inflammation in a murine model of non-infectious uveitis. In initial selections, specific VNARs that recognized human ICOSL were isolated from an immunized nurse shark phage display library and lead domains were identified following their performance in a series of antigen selectivity and bioassay screens. High potency in cell-based blocking assays suggested their potential as novel binders suitable for further therapeutic development. To test this hypothesis, surrogate anti-mouse ICOSL VNAR domains were isolated from the same phage display library and the lead VNAR clone selected screening in binding and ICOS/ICOSL blocking experiments. The VNAR domain with the highest potency in cell-based blocking of ICOS/ICOSL interaction was fused to the Fc portion of human IgG1 and was tested in a mouse model of interphotoreceptor retinoid-binding protein-induced uveitis. The anti-mICOSL VNAR Fc, injected systemically, resulted in a marked reduction of inflammation in treated mice when compared with untreated control animals. This approach inhibited disease progression to an equivalent extent to that seen for the positive corticosteroid control, cyclosporin A, reducing both clinical and histopathological scores. These results represent the first demonstration of efficacy of a VNAR binding domain in a relevant clinical model of disease and highlight the potential of VNARs for the treatment of auto-inflammatory conditions.

Citing Articles

Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research.

Shoemaker R, Larsen R, Larsen P Front Immunol. 2024; 15:1426656.

PMID: 39238639 PMC: 11374656. DOI: 10.3389/fimmu.2024.1426656.


Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy.

Smyth P, Ferguson L, Burrows J, Burden R, Tracey S, Herron U Front Pharmacol. 2023; 14:1296567.

PMID: 38116078 PMC: 10728302. DOI: 10.3389/fphar.2023.1296567.


Design and Construction of Antibody Fusion Proteins Incorporating Variable New Antigen Receptor (VNAR) Domains.

Ludwig S, Zhu A, Maremanda A, Dooley H, Spangler J Methods Mol Biol. 2023; 2720:17-33.

PMID: 37775655 DOI: 10.1007/978-1-0716-3469-1_2.


Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?.

Jiang X, Sun L, Hu C, Zheng F, Lyu Z, Shao J Mar Drugs. 2023; 21(9).

PMID: 37755109 PMC: 10532743. DOI: 10.3390/md21090496.


Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2.

Cabanillas-Bernal O, Valdovinos-Navarro B, Cervantes-Luevano K, Sanchez-Campos N, Licea-Navarro A Front Immunol. 2023; 14:1257042.

PMID: 37753081 PMC: 10518403. DOI: 10.3389/fimmu.2023.1257042.


References
1.
Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S . Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology. 2011; 411(1):132-41. DOI: 10.1016/j.virol.2010.12.034. View

2.
Patel A, Cholkar K, Agrahari V, Mitra A . Ocular drug delivery systems: An overview. World J Pharmacol. 2015; 2(2):47-64. PMC: 4289909. DOI: 10.5497/wjp.v2.i2.47. View

3.
Forrester J, Klaska I, Yu T, Kuffova L . Uveitis in mouse and man. Int Rev Immunol. 2013; 32(1):76-96. DOI: 10.3109/08830185.2012.747524. View

4.
Iwai H, Kozono Y, Hirose S, Akiba H, Yagita H, Okumura K . Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol. 2002; 169(8):4332-9. DOI: 10.4049/jimmunol.169.8.4332. View

5.
Liu J, Anderson G, Goldman E . Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library. BMC Biotechnol. 2007; 7:78. PMC: 2213646. DOI: 10.1186/1472-6750-7-78. View